STAAR Surgical (NASDAQ:STAA) Rating Reiterated by BTIG Research

STAAR Surgical (NASDAQ:STAAGet Rating)‘s stock had its “buy” rating reiterated by analysts at BTIG Research in a research note issued to investors on Saturday, TipRanks reports. They presently have a $98.00 target price on the medical instruments supplier’s stock. BTIG Research’s price target would indicate a potential upside of 58.78% from the company’s previous close.

STAA has been the topic of several other research reports. StockNews.com initiated coverage on shares of STAAR Surgical in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Zacks Investment Research raised shares of STAAR Surgical from a “sell” rating to a “hold” rating in a research note on Wednesday. Canaccord Genuity Group reduced their target price on shares of STAAR Surgical from $150.00 to $97.00 and set a “buy” rating on the stock in a research note on Friday, February 25th. Needham & Company LLC started coverage on shares of STAAR Surgical in a research note on Friday, April 8th. They issued a “buy” rating and a $87.00 target price on the stock. Finally, Benchmark upgraded shares of STAAR Surgical from a “hold” rating to a “buy” rating and set a $97.00 price target on the stock in a report on Monday, March 28th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $112.00.

STAAR Surgical stock traded down $3.94 during mid-day trading on Friday, reaching $61.72. 455,452 shares of the company’s stock traded hands, compared to its average volume of 457,020. The company has a market cap of $2.95 billion, a price-to-earnings ratio of 125.96 and a beta of 1.00. The stock has a 50 day moving average of $71.33 and a two-hundred day moving average of $87.64. STAAR Surgical has a 12-month low of $55.36 and a 12-month high of $163.08.

STAAR Surgical (NASDAQ:STAAGet Rating) last released its quarterly earnings results on Wednesday, February 23rd. The medical instruments supplier reported $0.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.10 by $0.02. The company had revenue of $59.00 million for the quarter, compared to the consensus estimate of $59.21 million. STAAR Surgical had a net margin of 10.63% and a return on equity of 11.84%. STAAR Surgical’s revenue was up 28.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.14 earnings per share. As a group, sell-side analysts forecast that STAAR Surgical will post 0.62 earnings per share for the current year.

In other STAAR Surgical news, VP James E. Francese sold 922 shares of the stock in a transaction dated Monday, March 21st. The shares were sold at an average price of $74.62, for a total transaction of $68,799.64. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.60% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the company. Allegheny Financial Group LTD purchased a new position in shares of STAAR Surgical in the 4th quarter valued at approximately $25,000. Rise Advisors LLC purchased a new position in shares of STAAR Surgical in the 4th quarter valued at approximately $25,000. Covestor Ltd purchased a new position in STAAR Surgical during the 4th quarter worth approximately $39,000. Lindbrook Capital LLC purchased a new position in STAAR Surgical during the 4th quarter worth approximately $59,000. Finally, Point72 Hong Kong Ltd purchased a new position in STAAR Surgical during the 4th quarter worth approximately $100,000. Institutional investors and hedge funds own 87.89% of the company’s stock.

About STAAR Surgical (Get Rating)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Read More

Analyst Recommendations for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.